Clinical Trials Logo

Malignant Pericardial Effusion clinical trials

View clinical trials related to Malignant Pericardial Effusion.

Filter by:
  • None
  • Page 1

NCT ID: NCT02132884 Terminated - Clinical trials for Stage IV Non-small Cell Lung Cancer

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Start date: March 2015
Phase: N/A
Study type: Interventional

This randomized clinical trial studies how well genetic sequencing-informed targeted therapy works in treating patients with stage IIIB-IV non-small cell lung cancer. Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of tumor cells that may have less harm to normal cells. Genetic sequencing may help identify these specific types of tumor cells in patients with non-small cell lung cancer.

NCT ID: NCT00132613 Completed - Clinical trials for Malignant Pericardial Effusion

Trial of Drainage With or Without Bleomycin Instillation for Malignant Pericardial Effusion

Start date: August 1999
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of pericardial instillation of bleomycin as a sclerosing agent after pericardial drainage for lung cancer-associated malignant pericardial effusion.

NCT ID: NCT00126581 Completed - Lung Adenocarcinoma Clinical Trials

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Start date: August 15, 2005
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well erlotinib hydrochloride with or without carboplatin and paclitaxel works in treating patients with stage III-IV non-small cell lung cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving erlotinib hydrochloride together with carboplatin and paclitaxel may kill more tumor cells than giving either drug alone.

NCT ID: NCT00004074 Completed - Clinical trials for Fallopian Tube Cancer

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Start date: August 1999
Phase: Phase 1
Study type: Interventional

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy